- $2.95m
- -$5.59m
- $9.14m
Aravive Inc expected to post a loss of 53 cents a share - Earnings Preview
Aravive Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aravive Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
Brief: Aravive Announces $10 Mln Registered Direct Offering Priced At--Market Under Nasdaq Rules
Aravive Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Aravive Appoints Scott Dove As Chief Operating Officer
Aravive Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Aravive Announces Positive Updated Data And New Biomarker Data From Phase 1B Study Of Batiraxcept In Clear Cell Renal Cell Carcinoma
U.S. RESEARCH ROUNDUP-Autoliv, Helix Energy Solutions Group, Oceaneering International
Brief: Aravive Announces First Patient Dosed In Phase 2 Study Of Batiraxcept In Clear Cell Renal Cell Carcinoma
Brief: Aravive Inc Files For Common Stock Shelf Of Up To 4.55 Million Shares By The Selling Stockholder - SEC Filing
Brief: Aravive Announces $10.0 Million Investment By Eshelman Ventures, Llc And Appointment Of Dr. Eshelman As Executive Chairman Of The Aravive Board Of Directors
Brief: Aravive Announces Positive Preliminary Data From Phase 1B Trial Evaluating Batiraxcept In Combination With Cabozantinib
Brief: Aravive Reports Q3 Results And Provides Corporate Updates
Brief: Aravive To Present New Data From Phase 1B Trial On AVB-500 In Clear Cell Renal Cell Carcinoma At Society For Immunotherapy Of Cancer
Brief: Aravive Announces First Patient Dosed In Phase 1B/2 Clinical Trial Of AVB-500
Aravive Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Aravive Achieves Second Development Milestone From 3D Medicines
U.S. STOCKS ON THE MOVE-Eli Lilly, Tesla, Darden Restaurant, Biogen